Mode
Text Size
Log in / Sign up

Microdosing psilocybin is associated with reported well-being and mental health benefits in some studiesReview of psilocybin microdosing for mental health and well-being

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that evidence for psilocybin microdosing is currently of low certainty due to reporting bias and lack of standardization.

This systematic review synthesized data from 3,262 participants to evaluate the effects of microdosing psilocybin (including magic mushrooms and truffles) on mental health, substance use, and general well-being. The authors identified that while some studies reported improvements in areas such as cognition, creativity, and physical health, these findings are based on a variety of self-reported measures.

Key data points include the finding that 86% of microdoser motivations were non-medical, while only 14% were related to medical diagnoses, primarily for mental health. Regarding safety, most studies did not report adverse events; where reported, these events were mostly mild. However, the evidence is characterized by extreme heterogeneity in dosing protocols and preparations.

The authors note significant limitations including a high risk of bias, the qualitative nature of much of the evidence, and low certainty overall. Because a causal effect cannot be inferred from this data, the results are not currently sufficient to establish clinical guidelines. The review emphasizes the necessity for well-powered randomized controlled trials with standardized protocols to determine definitive outcomes.

How this fits prior evidence

This systematic review addresses a gap in evidence regarding non-traditional pharmacological interventions for mental health and substance use disorders. While prior coverage has explored neurofeedback and iTBS for mental health and craving reduction, this review specifically examines the role of psilocybin microdosing. The findings are limited by low certainty and high heterogeneity, meaning they do not yet confirm or provide a definitive alternative to established treatments.

Many people are turning to microdosing—taking very small amounts of substances like psilocybin (found in magic mushrooms)—to improve their daily lives. Some users report feeling better mentally, more creative, or even less dependent on other substances. This review looked at 3,262 reports from adults who used these tiny doses.

While some studies did suggest improvements in areas like well-being and cognition, the researchers found a lot of hurdles in the data. Most of the evidence was based on people reporting their own feelings rather than strict clinical tests. Because different people used different amounts and methods, it is hard to say for sure what causes these effects.

Safety reports were mostly positive, with few studies noting any problems at all. When issues were reported, they were usually mild. However, because the current evidence is of low certainty, experts say we need more controlled trials with standard dosing before we can know if microdosing truly works for mental health.

What this means for you:
Early reports suggest some benefits from psilocybin microdosing, but the data is currently inconsistent and limited.

Common questions

What are people hoping to achieve by microdosing?

Most people who try microdosing do so for personal reasons rather than medical ones. About 86% of people reported non-medical motivations, while only 14% were seeking help for specific medical diagnoses, mostly related to improving their mental health.

Is it safe to microdose psilocybin?

The majority of studies included in this review did not report any adverse events. In the cases where side effects were reported, they were generally described as mild. However, because the evidence is limited, you should talk to your doctor about safety.

Does microdosing actually improve mental health?

Some studies suggest it may help with well-being and mental health, but the evidence is not very certain. Many reports relied on people's own feelings rather than strict measurements, and different dosing methods make it hard to prove a clear cause.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
IntroductionMicrodosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing protocols and preparations, adverse events, and competing interests.MethodsThis systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42023428107). Studies of adults microdosing psilocybin MM or truffles were eligible. Risk of bias was assessed across included studies.ResultsEleven articles (five quantitative and six qualitative studies) met inclusion criteria. Studies were conducted in the United States (n=4), Netherlands, Argentina, and internationally (n=2 each), and Slovenia (n=1) with a total sample of 3,262 adults. Some studies reported microdosing psilocybin MM or truffles may improve well-being, mental health, cognition, physical health, creativity, relationships, pain, curiosity, and substance dependence, and enhance senses among adults. However, the majority of evidence had at least some concerns for risk of bias or was qualitative and used a variety of self-reported outcome measures. Approximately 86% of microdoser motivations were non-medical and only 14% were related to medical diagnoses, mostly for mental health improvements. Extreme heterogeneity was identified across dosing protocols and preparations. The majority of studies did not report adverse events but for those reported, they were mostly mild. All but four studies declared no conflicts of interest and four did not disclose funding sources.DiscussionThe certainty of the evidence is low, and a causal effect of microdosing cannot be inferred. Future research should prioritize well-powered randomized controlled trials with standardized and substance-specific dosing protocols to determine causal relationships between microdosing MM or truffles and health outcomes. Mandatory reporting of adverse events and funding sources should be implemented to build the safety profile of microdosing MM and truffles and ensure transparency for potential conflicts of interest.Sytematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023428107.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.